Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use

Therapeutic Drug Monitoring

Volumn 28, Issue 2, 2006, Pages 155-163

  Musshoff, Frank ^a   Madea, Burkhard ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Blood analysis; Cannabinoids; Cannabis influence factor; Chronic use; Hair analysis; Urine analysis

Indexed keywords

CANNABIS;

CANNABIS ADDICTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG METABOLISM; DRUG URINE LEVEL; DRUG USE; FORENSIC MEDICINE; HAIR ANALYSIS; HUMAN; METABOLITE; PRIORITY JOURNAL; REVIEW; URINALYSIS;

HAIR; HUMANS; MARIJUANA ABUSE; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE DETECTION;

EID: 33748157825     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000197091.07807.22     Document Type: Review

References (77)

1. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327-360.
2. Iten PX. Fahren unter Drogen- oder Medikamenteneinfluss-Forensische Interpretation und Begutachtung. Institut für Rechtsmedizin der Universität Zürich; 1994.
3. Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids Delta-9-tetrahydrocannabinol, cannabidiol and cannabinol. In: Pertwee R, ed. Cannabinoids. New York: Springer-Verlag; 2005:657-690.
4. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992;16:276-282.
5. Hollister LE, Gillespie HK, Ohlsson A, et al. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol. 1981;21:171S-177S.
6. Lindgren JE, Ohlsson A, Agurell S, et al. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology (Berl). 1981;74:208-212.
7. Ohlsson A, Lindgren JE, Wahlen A, et al. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28:409-416.
8. Perez-Reyes M, Di GS, Davis KH, et al. Comparison of effects of marihuana cigarettes to three different potencies. Clin Pharmacol Ther. 1982;31:617-624.
9. Ohlsson A, Lindgren JE, Wahlen A, et al. Single dose kinetics of deuterium labeled delta 1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Mass Spectrom. 1982;9:6-10.
10. Wall ME, Sadler BM, Brine D, et al. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther. 1983;34:352-363.
11. Law B, Mason PA, Moffat AC, et al. Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol. 1984;36:289-294.
12. Widman M, Agurell S, Ehrnebo M, et al. Binding of (+)- and (-)-delta-1-tetrahydrocannabinols and (-)-7-hydroxy-delta-1-tetrahydrocannabinol to blood cells and plasma proteins in man. J Pharm Pharmacol. 1974;26:914-916.
13. Wahlqvist M, Nilsson IM, Sandberg F, et al. Binding of delta-1-tetrahydrocannabinol to human plasma proteins. Biochem Pharmacol. 1970;19:2579-2584.
14. Owens SM, McBay AJ, Reisner HM, et al. 125I radioimmunoassay of delta-9-tetrahydrocannabinol in blood and plasma with a solid-phase second-antibody separation method. Clin Chem. 1981;27:619-624.
15. Mason AP, McBay AJ. Cannabis: pharmacology and interpretation of effects. J Forensic Sci. 1985;30:615-631.
16. Giroud C, Menetrey A, Augsburger M, et al. Delta(9)-THC, 11-OH-Delta(9)-THC and Delta(9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. Forensic Sci Int. 2001;123:159-164.
17. Huang W, Moody DE, Andrenyak DM, et al. Simultaneous determination of delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol in human plasma by solid-phase extraction and gas chromatography-negative ion chemical ionization-mass spectrometry. J Anal Toxicol. 2001;25:531-537.
18. Hunt CA, Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther. 1980;215:35-44.
19. Lemberger L, Tamarkin NR, Axelrod J, et al. Delta-9-tetrahydrocannabinol: metabolism and disposition in long-term marihuana smokers. Science. 1971;173:72-74.
20. Ho BT, Fritchie GE, Kralik PM, et al. Distribution of tritiated-1 delta 9tetrahydrocannabinol in rat tissues after inhalation. J Pharm Pharmacol. 1970;22:538-539.
21. Agurell S, Nilsson IM, Ohlsson A, et al. On the metabolism of tritium-labeled 1-tetrahydrocannabinol in the rabbit. Biochem Pharmacol. 1970;19:1333-1339.
22. Johansson E, Noren K, Sjovall J, et al. Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr. 1989;3:35-38.
23. Kreuz DS, Axelrod J. Delta-9-tetrahydrocannabinol: localization in body fat. Science. 1973;179:391-393.
24. Harvey DJ, Leuschner JT, Paton WD. Gas chromatographic and mass spectrometric studies on the metabolism and pharmacokinetics of delta 1-tetrahydrocannabinol in the rabbit. J Chromatogr. 1982; 239:243-250.
25. Haggerty GC, Deskin R, Kurtz PJ, et al. The pharmacological activity of the fatty acid conjugate 11-palmitoyloxy-delta 9-tetrahydrocannabinol. Toxicol Appl Pharmacol. 1986;84:599-606.
26. Leighty EG, Fentiman AF Jr, Foltz RL. Long-retained metabolites of delta9- and delta8-tetrahydrocannabinols identified as novel fatty acid conjugates. Res Commun Chem Pathol Pharmacol. 1976;14:13-28.
27. Reiter A, Hake J, Meissner C, et al. Time of drug elimination in chronic drug abusers. Case study of 52 patients in a "low-step" detoxification ward. Forensic Sci Int. 2001;119:248-253.
28. Daldrup T, Thomsen T, Reudenbach G. Cannabiskonsum: Nachweisdauer, zeitlicher Verlauf, forensische Bedeutung. In: Arnold W, Poser WE, Möller MR, eds. Suchtkrankheiten. Diagnose, Therapie and analytische Nachweise. Berlin: Springer-Verlag; 1988:39-51.
29. Chiang CN, Rapaka RS. Pharmacokinetics and disposition of cannabinoids. NIDA Res Monogr. 1987;79:173-188.
30. Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol. 1992;16:228-235.
31. Huestis MA, Cone EJ. Urinary excretion half-life of 11-nor-9-carboxy- delta9-tetrahydrocannabinol in humans. Ther Drug Monit. 1998;20:570-576.
32. Johansson EK, Hollister LE, Halldin MM. Urinary elimination half-life of delta-1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. NIDA Res Monogr. 1989;95:457-458.
33. Manno JE, Manno BR, Kemp PM, et al. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9- tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol. 2001;25:538-549.
34. Dugan S, Bogema S, Schwartz RW, et al. Stability of drugs of abuse in urine samples stored at -20°C. J Anal Toxicol. 1994;18:391-396.
35. Golding Fraga S, Diaz-Flores Estevez J, Diaz Romero C. Stability of cannabinoids in urine in three storage temperatures. Ann Clin Lab Sci. 1998;28:160-162.
36. Skopp G, Pötsch L. Stability of 11-nor-delta(9)-carboxy- tetrahydrocannabinol glucuronide in plasma and urine assessed by liquid chromatography-tandem mass spectrometry. Clin Chem. 2002;48:301-306.
37. Skopp G, Pötsch L. An investigation of the stability of free and glucuronidated 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in authentic urine samples. J Anal Toxicol. 2004;28:35-40.
38. Cone EJ, Johnson RE, Paul BD, et al. Marijuana-laced brownies: behavioral effects, physiologic effects, and urinalysis in humans following ingestion. J Anal Toxicol. 1988;12:169-175.
39. Huestis MA, Mitchell JM, Cone EJ. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol. 1995;19:443-449.
40. Huestis MA, Mitchell JM, Cone EJ. Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana. J Anal Toxicol. 1996;20:441-452.
41. Smith-Kielland A, Skuterud B, Morland J. Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol. 1999;23:323-332.
42. Niedbala RS, Kardos KW, Fritch DF, et al. Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J Anal Toxicol. 2001;25:289-303.
43. Hollister LE, Kanter SL. Laboratory Verification of "heavy" and "light" users of cannabis. Drug Alcohol Depend. 1980;5:151-152.
44. Dackis CA, Pottash AL, Annitto W, et al. Persistence of urinary marijuana levels after supervised abstinence. Am J Psychiatry. 1982;139:1196-1198.
45. Ellis GM Jr, Mann MA, Judson BA, et al. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther. 1985;38:572-578.
46. Lafolie P, Beck O, Blennow G, et al. Importance of creatinine analyses of urine when screening for abused drugs. Clin Chem. 1991;37:1927-1931.
47. Kielland KB. [Urinary excretion of cannabis metabolites.] Tidsskr Nor Laegeforen. 1992;112:1585-1586.
48. Fraser AD, Coffin L, Worth D. Drug and chemical metabolites in clinical toxicology investigations: the importance of ethylene glycol, methanol and cannabinoid metabolite analyses. Clin Biochem. 2002;35:501-511.
49. Bell R, Taylor EH, Ackerman B, et al. Interpretation of urine quantitative 11-nor-delta-9 tetrahydrocannabinol-9-carboxylic acid to determine abstinence from marijuana smoking. J Toxicol Clin Toxicol. 1989;27:109-115.
50. Huestis MA, Cone EJ. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol. 1998;22:445-454.
51. Manno JE, Ferslew KE, Manno BR. Urine excretion patterns of cannabinoids and the clinical application of the EMIT dau cannabinoid urine assay for substance abuse treatment. In: Agurell S, Dewey WL, Willette R, eds. The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects. New York: Academic Press; 1984:281-290.
52. Fraser AD, Worth D. Urinary excretion profiles of 11-nor-9-carboxy- Delta9-tetrahydrocannabinol: a delta9-THCCOOH to creatinine ratio study. J Anal Toxicol. 1999;23:531-534.
53. Fraser AD, Worth D. Urinary excretion profiles of 11-nor-9-carboxy- Delta9-tetrahydrocannabinol: a Delta9-THC-COOH to creatinine ratio study #2. Forensic Sci Int. 2003;133:26-31.
54. Fraser AD, Worth D. Urinary excretion profiles of 11-nor-9-carboxy- Delta9-tetrahydrocannabinol. Study III. A Delta9-THC-COOH to creatinine ratio study. Forensic Sci Int. 2003;137:196-202.
55. Alburges ME, Peat MA. Profiles of delta 9-tetrahydrocannabinol metabolites in urine of marijuana users: preliminary observations by high performance liquid chromatography-radioimmunoassay. J Forensic Sci. 1986;31:695-706.
56. Skopp G, Pötsch L, Ganßmann B, et al. Freie und glucuronidierte Cannabinoide im Urin-Untersuchungen zur Einschätzung des Konsumverhaltens. Rechtsmed. 1999;10:21-28.
57. Hanson VW, Buonarati MH, Baselt RC, et al. Comparison of 3H-and 125I-radioimmunoassay and gas chromatography/mass spectrometry for the determination of delta 9-tetrahydrocannabinol and cannabinoids in blood and serum. J Anal Toxicol. 1983;7:96-102.
58. Foltz RL, McGinnis KM, Chinn DM. Quantitative measurement of delta 9-tetrahydrocannabinol and two major metabolites in physiological specimens using capillary column gas chromatography negative ion chemical ionization mass spectrometry. Biomed Mass Spectrom. 1983;10:316-323.
59. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH). J Anal Toxicol. 1992;16:283-290.
60. Smith ML, Wesenyalsh N, Barnes A, et al. Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations. Abstract book: 43rd International Meeting of the International Association of Forensic Toxicologists (TIAFT), Seoul (South Korea), 2005:82.
61. Daldrup T. Cannabis im Straßenverkehr; Abschlußbericht Z.B. 3.4721/03-2/93. Düsseldorf: Ministerium für Wirtschaft Mittelstand, Technologie und Verkehr NRW; 1996.
62. Drasch G, von Meyer L, Roider G, et al. Absolute Fahruntüchtigkeit unter der Wirkung von Cannabis-Vorschlag für einen Grenzwert. Blutalkohol. 2003;40:269-286.
63. Daldrup T, Meininger I. Begutachtung der Fahrtüchtigkeit unter Cannabis im Straßenverkehr. In: Berghaus G, Krüger H-P, eds. Cannabis im Straßenverkehr. Stuttgart: G. Fischer; 1998:153-178.
64. Daldrup T. Traffic accidents after cannabis use. Presentation 6th International Symposium on Advances in Legal Medicine (ISALM), Hamburg, September 19-24, 2005.
65. Daldrup T, Käferstein H, Köhler H, et al. Entscheidung zwischen einmaligem/gelegentlichem und regelmäßigem Cannabiskonsum. Blutalkohol. 2000;37:39-47.
66. Sachs H, Kintz P. Testing for drugs in hair. Critical review of chromatographic procedures since 1992. J Chromatogr B Biomed Sci Appl. 1998;713:147-161.
67. Madea B, Musshoff F. Haaranalytik-Technik und Interpretation in Medizin und Recht. Köln: Deutscher Ärzteverlag; 2004.
68. Nakahara Y, Takahashi K, Kikura R. Hair analysis for drugs of abuse. X. Effect of physicochemical properties of drugs on the incorporation rates into hair. Biol Pharm Bull. 1995;18:1223-1227.
69. Mieczkowski T, Newel R. Comparing hair and urine assays for cocaine and marijuana. Fed Probat. 1993;57:59-67.
70. Mieczkowski T, Newel R, Wraight B. Using hair analysis, urinalysis, and self-reports to estimate drug use in a sample of detained juveniles. Subst Use Misuse. 1998;33:1547-1567.
71. Musshoff F, Driever F, Lachenmeier K, et al. Results of hair analyses for drugs of abuse and comparison with self-reports and urine tests. Forensic Sci Int. 2006;156:118-123.
72. Mieczkowski T. A research note: the outcome of GC/MS/MS confirmation of hair assays on 93 cannabinoid (+) cases. Forensic Sci Int. 1995;70:83-91.
73. Uhl M. Tandem mass spectrometry: a helpful tool in hair analysis for the forensic expert. Forensic Sci Int. 2000;107:169-179.
74. Moore C, Guzaldo F, Donahue T. The determination of 11-nor-delta9- tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in hair using negative ion gas chromatography-mass spectrometry and high-volume injection. J Anal Toxicol. 2001;25:555-558.
75. Sachs H, Dressler U. Detection of THCCOOH in hair by MSD-NCI after HPLC clean-up. Forensic Sci Int. 2000;107:239-247.
76. Baptista MJ, Monsanto PV, Pinho Marques EG, et al. Hair analysis for delta(9)-THC, delta(9)-THC-COOH, CBN and CBD, by GC/MS-EI. Comparison with GC/MS-NCI for delta(9)-THC-COOH. Forensic Sci Int. 2002;128:66-78.
77. Uhl M, Sachs H. Cannabinoids in hair: strategy to prove marijuana/hashish consumption. Forensic Sci Int. 2004;145:143-147.